Sign up
Pharma Capital

WideCells ready to ink deal that expands its reach to the Middle East, Africa and Asia-Pacific

“This agreement highlights how rapidly we can grow and we are committed to securing similar commercial partnerships as we transform the value fundamentals of our company," said WideCells chief executive, João Andrade
skyline of dubai after dark
The new operation will be run from Dubai (pictured)

WideCells Group PLC is in the process of inking a deal worth an initial £255,000 that will take its stem cell services into the Middle East, North Africa and Asia-Pacific regions.

WATCH: WideCells makes move into North Africa, Middle East and Asia-Pacific

It hopes to have brokered a formal agreement with Gulf-based White Apex General Trading by the end of the month, which will trigger the first payment to the UK firm.

The tie-up will cover stem cell collection and dispatch, the sale and distribution of a synthetic bone graft called INDUS and the introduction to local insurance companies to the WideCells product CellPlan, which funds stem cell treatments.

New academy 

The formation of a regional training facility called the Wideacademy would trigger a further payment of £250,000, which could occur before the year-end.

The new operation will be run out of Dubai with Dr Ahmed Alawi, a preeminent doctor in the stem cell sector, heading it.

“This agreement highlights how rapidly we can grow and we are committed to securing similar commercial partnerships as we transform the value fundamentals of our company," said WideCells chief executive, João Andrade.

Shares were up 0.9% to 14p in late afternoon trade.

--Updates for video link and share price--

Ian_55ae0ddd437b7.jpg
Why Invest In WideCells Group? Read More Here

Register here to be notified of future WDC Company articles
View full WDC profile

WideCells Group Timeline

Newswire

WideCells expands its reach to Spain

View All

Related Articles

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.